Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
주식 순위 #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
주가
$150.78
마지막 동기화: 2026-09-18
시가총액
$187.20B
변동 (1일)
-0.08%
변동 (1년)
32.15%
국가
US
거래 Gilead Sciences, Inc. (GILD)

카테고리

Gilead Sciences, Inc. (GILD)의 영업이익률
September 2026 기준 영업이익률 TTM: -4.90%
Gilead Sciences, Inc.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 -4.90%입니다. 2024년 말 기준 영업이익률은 5.78%였습니다.
Gilead Sciences, Inc.의 영업이익률 기록 (2000 ~ 2026)
매년 말 영업이익률
연도 영업이익률 변화
2026 (TTM) -4.90% -114.39%
2025 34.04% 488.93%
2024 5.78% -79.39%
2023 28.05% 4.39%
2022 26.87% -26.02%
2021 36.32% 120.25%
2020 16.49% -13.66%
2019 19.10% -48.46%
2018 37.06% -31.50%
2017 54.10% -6.76%
2016 58.02% -14.68%
2015 68.00% 10.88%
2014 61.33% 51.84%
2013 40.39% -2.27%
2012 41.33% -8.56%
2011 45.20% -9.31%
2010 49.84% -0.99%
2009 50.34% 0.28%
2008 50.20% -1.90%
2007 51.17% -304.11%
2006 -25.07% -145.85%
2005 54.68% 15.46%
2004 47.36% -359.08%
2003 -18.28% -205.36%
2002 17.35% -133.60%
2001 -51.63% 93.01%
2000 -26.75% 0.00%
유사 기업 또는 경쟁사의 영업이익률
회사 영업이익률 영업이익률 차이 국가
43.92% -108.96%
US
26.81% -105.47%
US
29.32% -105.98%
US
26.59% -105.43%
CH
16.65% -103.40%
US
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.